Altimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026

Altimmune (Nasdaq: ALT) will report its third quarter 2026 financial results and provide a business update on November 12, 2026.

Rhea-AI Summary

Altimmune (Nasdaq: ALT) will report its third quarter 2026 financial results and provide a business update on November 12, 2026. Management will host a conference call at 8:30 a.m. ET that day. A live webcast will be available on the company’s Investor Relations website, with a replay available shortly afterward for up to three months.

Key Terms

glucagon/glp-1 receptor agonist, metabolic dysfunction-associated steatohepatitis (mash), alcohol use disorder (aud), alcohol-associated liver disease (ald)

4 terms

glucagon/glp-1 receptor agonist medical

"an investigational balanced 1:1 glucagon/GLP-1 receptor agonist"

A glucagon/GLP-1 receptor agonist is a single drug molecule that activates two different hormone receptors: the glucagon receptor and the glucagon-like peptide-1 (GLP-1) receptor. Activating the GLP-1 receptor enhances glucose-dependent insulin release and slows gastric emptying, while activating the glucagon receptor raises metabolic rate and influences glucose production; the combined activity produces a mix of those physiological effects determined by how strongly the drug stimulates each receptor. These agents are usually peptide-based and designed so the relative strength (balance) of glucagon versus GLP-1 stimulation determines their clinical effects and side-effect profile.

metabolic dysfunction-associated steatohepatitis (mash) medical

"treatment of metabolic dysfunction-associated steatohepatitis (MASH)"

Metabolic dysfunction-associated steatohepatitis (MASH) is a liver condition characterized by inflammation and fat buildup caused by metabolic issues like obesity and insulin resistance. It can lead to liver damage over time, similar to rust gradually weakening metal. Because it is linked to widespread health problems such as diabetes and heart disease, MASH is becoming an important factor in overall health risks and healthcare costs, which can impact economic and investment considerations.

alcohol use disorder (aud) medical

"trial in alcohol use disorder (AUD)"

A chronic medical condition in which a person repeatedly drinks alcohol in a way that they cannot control, continuing despite harm to their health, work or relationships; it ranges from risky drinking to severe dependence. Investors should care because AUD drives demand for treatments, public health spending, workplace productivity losses and regulatory attention—similar to how a persistent mechanical problem increases repair and operating costs, it creates long-term market and policy implications for healthcare, insurers and employers.

alcohol-associated liver disease (ald) medical

"studied in alcohol-associated liver disease (ALD)"

Alcohol-associated liver disease (ALD) is a spectrum of liver damage caused by regular, excessive alcohol use that ranges from fatty liver (steatosis) to alcoholic hepatitis and progressive fibrosis or cirrhosis. Damage occurs because alcohol and its breakdown products injure liver cells, trigger inflammation, and lead over time to scarring that can impair liver function; the condition is diagnosed by medical history, blood tests, imaging, and sometimes liver biopsy. Severity varies widely—early stages can be reversible with reduced alcohol exposure, while advanced fibrosis or cirrhosis represents permanent structural damage and carries risk of liver failure and related complications.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MORRISTOWN, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a biopharmaceutical company advancing pemvidutide, an investigational balanced 1:1 glucagon/GLP-1 receptor agonist, in serious liver diseases, today announced that it will report its third quarter 2026 financial results on Thursday, November 12, 2026.

Altimmune management will host a conference call at 8:30 a.m. ET on November 12 to discuss the financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website.

Participants who would like to join the call may register here to receive dial-in numbers and a unique PIN. A replay will be available on the Investor Relations website shortly after the call for up to three months.

About Altimmune
Altimmune is a biopharmaceutical company developing pemvidutide for patients with serious liver diseases. Pemvidutide, a unique dual-action investigational therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio, is in late-stage clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), recently showed robust results in the RECLAIM Phase 2 trial in alcohol use disorder (AUD) and is being studied in alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on X

Investor Contact:
Luis Sanay, CFA
ir@altimmune.com

Media Contact:
Marisa Sharkey
media@altimmune.com